OMER Omeros Corporation

13.29
-0.1  -1%
Previous Close 13.39
Open 13.28
Price To Book -7.3
Market Cap 651333730
Shares 49,009,310
Volume 602,531
Short Ratio
Av. Daily Volume 939,730

SEC filingsSee all SEC filings

  1. 8-K - Current report 181186875
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169906
  3. 8-K - Current report 181169726
  4. 8-K - Current report 181109340
  5. CT ORDER - Confidential treatment order 181107099

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation announced January 2, 2018.
OMS721
Hematopoietic stem cell-associated TMA (HSCT-TMA)
Phase 3 trial enrollment initiated February 2018. Phase 2 data released October 1, 2018 showed only marginal improvement compared with placebo.
OMS721
IgA nephropathy
Phase 2 data released October 2016.
OMS721
Kidney disorders
Approved June 2, 2014.
Omidria
Cataract surgery
Phase 3 enrollment has opened - noted March 16, 2017.
OMS721
Atypical hemolytic uremic syndrome (aHUS)
Phase 1 trial initiation announced July 17, 2018.
OMS527
Nicotine Addiction

Latest News

  1. Omeros Announces Research Collaboration with University of Cambridge
  2. Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
  3. Omeros Announces Additions to Senior Management Team
  4. Edited Transcript of OMER earnings conference call or presentation 9-Nov-18 1:30pm GMT
  5. New Research Coverage Highlights Omeros, Apple, Bio-Rad Laboratories, Cott, Darling Ingredients, and Osisko Gold Royalties — Consolidated Revenues, Company Growth, and Expectations for 2018
  6. Does Omeros Corporation’s (NASDAQ:OMER) CEO Salary Reflect Performance?
  7. Here's Why Omeros Corporation Fell as Much as 24.5% Today
  8. The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall
  9. Omeros Announces Pricing of $210 Million Offering of Convertible Senior Notes Due 2023
  10. Today's Research Reports on Trending Tickers: Omeros and Spectrum Pharmaceuticals
  11. Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates
  12. Omeros: 3Q Earnings Snapshot
  13. Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023
  14. Omeros Corporation Reports Third Quarter 2018 Financial Results
  15. Omeros Corporation to Announce Third Quarter 2018 Financial Results on November 9, 2018
  16. Why Omeros Corporation Fell 37.4% in October
  17. FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
  18. New Research: Key Drivers of Growth for Hecla Mining, Atlas Air Worldwide, Encana, Omeros, Lowe's Companies, and Oaktree Specialty Lending — Factors of Influence, Major Initiatives and Sustained Production
  19. Are These Beaten-Down Clinical-Stage Biotech Stocks Buys?
  20. Why Omeros Corporation Stock Is Bouncing Back Today

SEC Filings

  1. 8-K - Current report 181186875
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181169906
  3. 8-K - Current report 181169726
  4. 8-K - Current report 181109340
  5. CT ORDER - Confidential treatment order 181107099
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181005272
  7. 8-K - Current report 181005122
  8. 8-K - Current report 18905004
  9. 8-K - Current report 18856610
  10. 8-K - Current report 18850015